Actinium Doses the First Patient in the Fourth, Final Cohort of Its Actimab-A Trial

Actinium Pharmaceuticals, Inc. , a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced that the first patient was successfully treated with Actimab-A drug candidate in the fourth and last cohort of the ongoing Phase 1/2 trial of Actimab-A. Actimab-A is being developed for newly diagnosed AML patients over the age of 60 ineligible for standard induction chemotherapy.

http://ift.tt/1EFbtKN